BIOVENTRIX, INC.

S-1/A amended

BioVentrix, Inc. is conducting an initial public offering (IPO) for its common stock, aiming to raise capital to advance its medical device programs, including the Revivent System for heart failure patients. The company is in a pivotal trial for the Revivent System in the U.S. and has a CE mark in Europe. The IPO includes underwriting terms, warrants, and a potential Nasdaq listing. The filing highlights risks related to clinical trial outcomes, regulatory approvals, and market competition.

S-1 filed

BIOVENTRIX, INC. is conducting an initial public offering (IPO) of its common stock, aiming to raise capital for its medical device initiatives focused on treating heart failure patients with reduced ejection fraction (HFrEF). The company's lead product, the Revivent System, has received a CE mark in Europe and is in a pivotal trial in the U.S. The IPO includes underwriting details, a warrant for underwriters, and a 30-day over-allotment option. The company anticipates listing on Nasdaq but faces risks related to FDA approval, clinical trial outcomes, and market competition.

DRS/A amended

BIOVENTRIX, INC. is seeking to raise capital through an initial public offering (IPO) of its common stock, aiming to commercialize its Revivent System, a medical device for restoring left ventricular function in heart failure patients. The company is in the pivotal trial phase for the Revivent System in the U.S. and has a CE mark in Europe. It also holds rights to Alginate, a hydrogel-based treatment for HFrEF patients without anterior scarring. The IPO is structured with underwriting discounts, a warrant for underwriters, and a 30-day over-allotment option. The company emphasizes its focus on addressing high mortality rates in HFrEF patients under current standards.

DRS/A amended

BIOVENTRIX, INC. is undergoing an initial public offering (IPO) for its common stock, with the current filing (DRS/A) representing an amendment to the previous draft registration statement (DRS). The company focuses on developing medical devices to restore left ventricular function in heart failure patients, with its lead product, the Revivent System, in a pivotal trial in the U.S. The filing outlines the IPO structure, underwriting terms, and risks associated with the offering, including regulatory uncertainties and clinical trial outcomes.

DRS filed

BioVentrix, Inc. is a clinical-stage medical device company developing the Revivent System, a device to restore left ventricular function in heart failure patients. The company is conducting a pivotal RELIVE Trial under FDA Breakthrough Therapy Designation to support Pre-Market Approval (PMA) for its Revivent Therapy. This is the company's initial public offering (IPO) with an assumed initial price range, aiming to list on Nasdaq. The filing highlights risks related to clinical trial outcomes, regulatory approvals, and market uncertainties.